Expanded Agreement Gives St. Jude Medical Broader Use of SurModics' Cardiac Technologies
April 16, 2007 - SurModics Inc., a provider of surface modification and drug delivery technologies to the healthcare industry, announced the signing of an expanded corporate technology agreement with St. Jude Medical Inc.
Under the agreement, SurModics has licensed multiple technologies for use in products being developed in St. Jude Medical's Cardiovascular and Cardiac Rhythm Management divisions.
SurModics Inc.'s technologies include biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics.
For more information: www.surmodics.com.
More like this
- SurModics Inc.
- SurModics Licenses Hydrophilic Coating for Elixir’s Drug-Eluting, Bare Metal Stents
- SurModics, Paragon Develop DES to Combat Late Stent Thrombosis
- SurModics, Nexeon MedSystems Collaborate to Develop Renal Artery Stent
- First Human Use Announced of Finale Prohealing Coating Technology on PROTEX Stent